No Detail Found!

Analgesic effect of neoadjuvant denosumab in Grade III giant cell tumor of bone.

Author(s)
Badaruddin Sahito Orthopaedic Surgery, Dow University of Health Sciences/Civil Hospital Karachi, Pakistan
Sana Shahid General Surgery, Dow University of Health Sciences/Civil Hospital Karachi, Pakistan
Arsia Hanif General Surgery, Dow University of Health Sciences/Civil Hospital Karachi, Pakistan
Nasim Munshi Orthopaedic Surgery, Ziauddin Hospital, Karachi, Pakistan
Muhammad Soughat Katto Orthopaedic Surgery, Dow University of Health Sciences/Civil Hospital Karachi, Pakistan
Azam Kamboh Orthopaedic Surgery, Dow University of Health Sciences/Civil Hospital Karachi, Pakistan
Sheikh Muhammad Ebad Ali Emergency Medicine, Aga Khan University Hospital, Karachi, Pakistan
Abstract
Objective: To assess the pain relief after denosumab use in grade III giant cell tumor of bone (GCT-B). Study Design: Retrospective Cohort study. Setting: Department of Orthopedic Surgery Dow University of Health Sciences / Dr Ruth KM Pfau Civil Hospital Karachi. Period: 2018 May to 2020 June. Material & Methods: Total 27 patients were included in the study with diagnosis of grade III GCT-B. Patients with Stage I & II excluded from study. Results: After the first dose of Denosumab, 24 (88.9%) patients reported no pain relief while the other 3 (11.1%) patients had mild pain. A second dose of Denosumab was given to these patients. After the second dose, 3 (11.1%) patients scored mild pain and 24 patients had a score of =4 on VAS. The pain severity reduced significantly after administration of 2 nd dose of Denosumab (p=0.019). Pain severity was remeasured after the third dose of Denosumab where they had VAS of 0 to 6, with inconsistent use of simple analgesics. The pain severity reduced significantly after administration of 3 rd dose of Denosumab (p=0.001). Conclusion: We conclude that denosumab have excellent analgesic effect in grade III giant cell tumor of bone. We recommend the use denosumab in perioperative therapy for grade III GCT-B bone and we found analgesic effect as additional one. It may gain some time for patient specially in developing nations where oncology surgery centers are limited. It also reduces the use of NSAIDS during window period of definitive surgery.
Publication Details
Page(s) 613-617
Published Journal: Professional Medical Journal, Volume: 29, Issue: 5, Year: 2022

Request the full text from PASTIC

Keywords
Denosumab, Giant Cell Tumor., Analgesic Effect
0

Citations

0

Downloads

42

Views